ACUTAAS CHEMICALS LIMITED
ACUTAAS
Quarterly Score
Showing the latest 12 quarterly points (newest to oldest).
Score context (latest 12 quarters)
Management guides for continued strong growth in FY24 (Pharma 22-25%, Specialty 25-30%). EBITDA margins for the pharma business are targeted to sustain 23%+ (achieved in Q4 FY23), and specialty chemicals margins are targeted to improve 50-100 bps QoQ to 18-19% in FY24. Significant capex of over INR 200 crores is planned for FY24, including for the greenfield Ankleshwar facility, solar energy, and future electrolyte expansion. Electrolyte additives are moving to commercial orders, and the expanded Fermion contract commences supply in Q3 FY24 (full capacity in FY25).
Rationale
- Strong Q4 & FY23 Financial Performance: Q4 FY23 revenue grew 29.8% YoY to INR 186 crores, with full-year FY23 revenue growing 18.6% YoY to INR 617 crores, driven by a 22% YoY growth in the advanced pharmaceutical intermediates business.
- Significant Margin Expansion & Recovery: Q4 FY23 EBITDA margin expanded to 21.9% (vs. 18% in Q4 FY22 and 20.2% in Q3 FY23), representing a 380 basis point improvement from Q1 FY23. Pharma business EBITDA margin reached 23.6% in Q4 FY23.
Management reiterated FY24 guidance for 20% to 25% revenue growth and greater than 21% EBITDA margin. This confidence is driven by new product additions, maturing long-term validations, the Fermion contract (Q4 FY24 onwards), and anticipated electrolyte additive contracts (H2 FY24 onwards).
Rationale
- Delivered 8.7% YoY revenue growth to Rs. 142 crores in Q1 FY24, despite a deflationary pricing environment and Q1 being a historically weak quarter.
- Reported 9.7% YoY EBITDA growth to Rs. 25.2 crores and 12% YoY PAT growth to Rs. 16.6 crores, with EBITDA margins expanding by 20 basis points to 17.7% and PAT margins to 11.7%, despite higher employee costs (including a 25% minimum wage hike).
Full-year FY24 revenue growth target modified downwards from 22-25% to 18-22%. The company anticipates 'stronger performance in the second half of the year' and a 'strong recovery on sequential basis' due to a 'clear order book in hand'. Ankleshwar Block 1 is expected to operationalize early Q4 FY24, contributing to revenue from Q4 FY24, with full ramp-up by FY25. Fermion contract shipments start Q4 FY24, fully ramped by H2 FY25. Electrolyte business production to start Q4 FY24. Baba Fine Chem is expected to see exponential growth from FY25 after FY24 consolidation.
Rationale
- Q2 Profitability Deterioration: Gross Margin significantly declined to 41% in Q2 FY24 (vs. implied ~48.3% in Q2 FY23) and EBITDA Margin fell to 14.4% (vs. 19.1% in Q2 FY23), leading to a negative reported PAT of Rs. 17 crores before adjustment for a one-off JV impairment.
- Full-Year Guidance Cut: Management modified FY24 revenue growth target downwards from 22-25% to 18-22%, explicitly stating it was due to 'pricing pressure marginally scaled back the growth' and 'top line erosion'.
FY24 revenue growth guidance maintained at 15-18% (9M growth at 14.4%), with FY25 revenue guidance of 17-22%. Management expects EBITDA margins to recover to 18-20% in Q4 FY24 and target 23% long-term. Strong revenue visibility for FY25 from Apixaban ramp-up and new Fermion & Electrolyte projects.
Rationale
- Revenue from operations grew 9.2% YoY to Rs. 166.5 crores in Q3 FY24, driven by a strong 25% YoY volume growth, indicating market traction despite significant pricing pressure.
- EBITDA margin sequentially expanded by 150 basis points to 15.9% in Q3 FY24, suggesting a bottoming out or recovery in profitability despite a YoY decline from 20.2%.
Provided new guidance for FY25 revenue growth of 25%, with growth heavily weighted towards H2 (40:60 split). Secured confirmed order for CDMO project ramping up from H2 FY25, and a firm order for electrolyte additives starting Q2 FY25, targeting 100% growth in FY26. Expected normalization of Baba Fine Chem sales from H2 FY25.
Rationale
- Q4 FY24 revenue grew strongly by 20.7% YoY and 35.2% sequentially to INR224.9 crores, with full-year FY24 revenue up 16.3% to INR717 crores.
- EBITDA margins showed strong sequential recovery, expanding by 326 basis points to 19.2% in Q4 FY24, driven by operating leverage and cost control, with management targeting a return to historical margin levels.
Management reaffirmed full-year FY25 revenue growth guidance of more than 25%, based on the current order book. They anticipate sequential revenue growth from Q1 to Q4, and expect over 200 basis points improvement in EBITDA margin sequentially from Q2 FY25 onwards.
Rationale
- Balance sheet significantly strengthened by retiring all debt post-QIP, resulting in a net cash position of Rs. 385 crores as of June, substantially de-risking the company.
- Management reaffirmed a strong full-year FY25 revenue growth guidance of 25%+ with confidence, citing a healthy order book and historical sequential growth trends from Q1.
FY25 revenue growth guidance revised upwards from 25% to 30%, backed by strong order book and forecast. Management aims for an average 25% annual CAGR in the medium term and 25-30% EBITDA margins in the next three years. Electrolyte additive CAPEX for VC and FEC (2000 MT each) expected completion by Q1 FY26.
Rationale
- Delivered stellar Q2 FY25 revenue growth of 43.2% YoY (246.7 crore) and H1 FY25 revenue growth of 29.8% YoY (423.4 crore), demonstrating strong operational performance amidst challenging industry conditions.
- Achieved significant margin expansion in Q2 FY25, with Gross Margin at 43.4% (+239 bps YoY, +136 bps QoQ), EBITDA Margin at 19.8% (+543 bps YoY, +312 bps QoQ), and PAT Margin at 15.2% (+668 bps YoY, +682 bps QoQ), driven by better product mix and operating leverage.
FY25 growth guidance revised upward from 30% to 35%. CDMO business is projected to reach INR 1,000 crores by FY28, with several new projects expected to begin commercialization by FY26. Electrolyte additive CAPEX is on track for completion by H1 FY26. Demand for apixaban and rivaroxaban intermediates is expected to ramp up through FY26.
Rationale
- Revenue from operations grew 65.2% year-over-year and 11.5% sequentially in Q3 FY25 to INR 275 crores, demonstrating robust top-line performance.
- EBITDA margins expanded significantly to 25% (+904 bps YoY, +198 bps QoQ) in Q3 FY25, driven by improved gross margins (46.2%) and operating leverage from a better product mix, indicating strong profitability and operational efficiency.
Management guided for 25% revenue growth in FY26, with further improvements in full-year EBITDA margins (expected to be higher than FY25's 23%). New CDMO contracts are expected to contribute revenue in H2 FY26, and the electrolyte additives business is scheduled to commence production in H2 FY26 from the new brownfield plant at Jhagadia. FY26 capex is expected to be around INR 200 crores, funded by QIP proceeds and internal accruals.
Rationale
- Exceptional Revenue Growth: FY25 revenue crossed INR 1,000 crores, growing by a stellar 40.3% YoY to INR 1,006.9 crores, with Q4 FY25 revenue growing 37.1% YoY to INR 308.5 crores, driven significantly by the Pharma Intermediates segment (+50% YoY in FY25).
- Strong Profitability & Margin Expansion: FY25 EBITDA grew 80.6% YoY to INR 232.1 crores, and Q4 FY25 EBITDA nearly doubled YoY to INR 85 crores, with EBITDA margins expanding by 835 bps YoY to 27.5% (Q4) due to better product mix and operating leverage. FY25 PAT nearly doubled to INR 160.4 crores.
Management reaffirmed FY26 revenue growth guidance of 25% and committed to driving further margin improvements. New CDMO projects and electrolyte additives are expected to contribute revenue from Q4 FY26, while the semiconductor JV commercial production is anticipated by late 2026 or early 2027.
Rationale
- Revenue grew by 17.3% YoY to INR207 crores in Q1 FY26, with the pharmaceutical intermediates segment leading with 23.3% YoY growth.
- Gross margin expanded significantly by 1,117 bps YoY to 53.2%, EBITDA margin by 785 bps YoY to 24.6%, and PAT margin by 1,292 bps YoY to 21.2%, driven by cost optimization and improved product mix.
FY26 revenue growth maintained at ~25% (H1 at 21.3% implies H2 acceleration). FY26 EBITDA margin guidance revised upwards to 28-30%. FY26 capex maintained at ~INR 250 crores (H1 at INR 141 crores). Electrolyte additive production expected Q4 FY26 with full contribution in FY27. Indichem JV (Korea) revenue expected from H2 FY27. New CDMO products expected to contribute by Q4 FY26 (subject to regulatory approvals). Working capital for full year expected to be 95-105 days.
Rationale
- Q2 FY26 revenue grew 24.1% YoY to INR 306.2 crores, and H1 FY26 revenue grew 21.3% YoY to INR 513.4 crores, primarily driven by robust performance in the Advanced Pharmaceutical Intermediates segment (+27.1%).
- Gross margin expanded by 1,232 bps YoY to 55.8% in Q2 FY26, and EBITDA margin expanded by 1,130 bps YoY to 31.1% in Q2 FY26, leading to a near doubling of EBITDA (+2x) and PAT (+91.3%) YoY.
Full-year FY26 revenue guidance raised from 25% to around 30% growth. Full-year FY26 EBITDA margin guidance upgraded from 28-30% to 32-35%. Total capex for FY26 is expected to be around INR 220 crores (revised from INR 250 crores) due to spill-over of Battery Chemical Phase 2 and Pilot Plant capex. CDMO business target of INR 1,000 crores by FY28 maintained, with four new validated products expected to contribute from FY27. Battery chemicals commercial operations (VC and FEC) expected to ramp up significantly from Q1 FY27, with orders in hand for FY27; two more battery chemical products expected to contribute from mid-FY27. Pilot plant capex completion delayed to Q1 FY27. Indichem JV capex progressing as per plan, completion by end of calendar year 2026.
Quarter summary
- Company is evolving into a diversified chemicals company with three independent, self-sustaining growth verticals: Pharmaceutical Intermediates (core & CDMO), Battery Chemicals, and Semiconductor Chemicals, expected to contribute meaningfully by FY28.
- Inauguration of the new block at the Jhagadia facility dedicated to battery chemicals on January 19, 2026, marking the commencement of operations in a key new growth area.
Rationale
- Reported exceptional Q3 FY26 revenue of INR 393.2 crores, a strong 43% Y-o-Y growth, and 9M FY26 revenue of INR 906.6 crores, up 29.8% Y-o-Y, demonstrating robust top-line expansion.
- Achieved highest-ever margins in Q3 FY26: Gross Margin at 57% (+1,073 bps Y-o-Y), EBITDA Margin at 38.3% (+1,335 bps Y-o-Y), and PAT Margin at 27% (+1,049 bps Y-o-Y), driven by improved product mix and operational efficiency (e.g., energy cost savings).
Future Growth Prospects
Catalysts (next 12-24 months)
Swipe or use arrows to browse all triggers.
Jhagadia Battery Chemicals Ramp-up
Timeline
- in progressQ1 FY26 · concall
Electrolyte additive capex at our site in Jhagadia is on track and expected to be completed by Q3 FY '26.
- in progressQ2 FY26 · concall
Production is expected to commence in Q4 FY '26 once our ongoing capex is completed.
Timeline shifted slightly to Q4 FY26
Show full timeline (3)
- commissionedQ3 FY26 · concall
First phase of electrolyte block is inaugurated on 19 January 2026. Second phase expected within 6 months.
Inaugurated; ramp up confirmed for Q1 FY27
Supporting evidence
• Q3 FY26 · concall · We inaugurated a new block at our Jhagadia facility dedicated exclusively to battery chemicals on 19 January 2026. We expect this business to ramp up significantly from Q1 FY '27.
CDMO Pipeline Contribution
Timeline
- in progressQ1 FY26 · concall
Dispatched a couple of validation batches for new products.
- scaledQ3 FY26 · concall
Four products already validated; expect top line contribution from FY27.
Validation complete for initial products
Supporting evidence
• Q3 FY26 · concall · Four products which have been validated in the current financial year should start contributing to the top line from FY '27. Takes us to our CDMO guidance of INR1,000 crores by FY '28.
Indichem South Korea JV
Timeline
- announcedQ1 FY26 · concall
Entering joint venture in South Korea named Indichem; investing KRW30 billion for a 75% stake.
- in progressQ2 FY26 · concall
Groundbreaking ceremony took place last month... expected to start contributing to revenues from H2 FY '27.
Project execution started
Show full timeline (3)
- in progressQ3 FY26 · concall
Invested INR130 crores; expect to complete capex and start business by end of this calendar [2026].
Over 65% of investment deployed
Supporting evidence
• Q3 FY26 · concall · Till now, we have invested close to INR130 crores in this joint venture. Total investment announced was around INR200 crores.
Variant perception
Non-consensus viewThe market may underappreciate the velocity of margin expansion (record 38.3%) and the high asset-turn (1:1 to 2.5x) expected from non-pharma verticals.
- Indichem JV margins are expected to be significantly higher than pharma, potentially rerating the blended EBITDA profile.
Show more (1)Hide extras
- Acutaas is the first non-Chinese player to develop global-scale electrolyte additives, capturing a unique niche.
- Concentration risk in the top CDMO product remains high until the four new FY27 molecules scale meaningfully.
Show more (1)Hide extras
- Delay in equipment arrival for the Sachin pilot plant plant could ripple into future CRAMS project timelines.
Quick takeaway
Consistent execution of core pharma CDMO business reaching ~30% revenue growth.
Risk watch: Slower than expected utilization ramp-up at the 442 KL Ankleshwar facility.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Consistent execution of core pharma CDMO business reaching ~30% revenue growth.
- Full benefit of solar power plants driving EBITDA margins to the 32-35% range.
Risks
- Slower than expected utilization ramp-up at the 442 KL Ankleshwar facility.
- Potential delays in validation of additional CDMO molecules in the pipeline.
Quick takeaway
Early revenue breakthrough in Indichem South Korea JV prior to H2 FY27.
Risk watch: Intense global competition in semiconductor purity levels affecting pricing.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Early revenue breakthrough in Indichem South Korea JV prior to H2 FY27.
- Rapid scaling of battery chemical VC/FEC orders beyond initial 2,000 MT capacity.
Risks
- Intense global competition in semiconductor purity levels affecting pricing.
- Raw material cost volatility if China+1 domestic sourcing faces capacity constraints.
Quick takeaway
Extended trial/validation quarter for Jhagadia electrolyte block beyond Q4 FY26.
Risk watch: High debtor days (100) and working capital (111 days) straining liquidity.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Extended trial/validation quarter for Jhagadia electrolyte block beyond Q4 FY26.
- Geopolitical shifts impacting the export-heavy (74%) revenue model.
Risks
- High debtor days (100) and working capital (111 days) straining liquidity.
- Slugish photoresist demand from heraeus affecting Baba Fine Chemicals recovery.
Quick takeaway
Consistent execution of core pharma CDMO business reaching ~30% revenue growth.
Risk watch: Slower than expected utilization ramp-up at the 442 KL Ankleshwar facility.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Consistent execution of core pharma CDMO business reaching ~30% revenue growth.
- Full benefit of solar power plants driving EBITDA margins to the 32-35% range.
Risks
- Slower than expected utilization ramp-up at the 442 KL Ankleshwar facility.
- Potential delays in validation of additional CDMO molecules in the pipeline.
Quick takeaway
Early revenue breakthrough in Indichem South Korea JV prior to H2 FY27.
Risk watch: Intense global competition in semiconductor purity levels affecting pricing.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Early revenue breakthrough in Indichem South Korea JV prior to H2 FY27.
- Rapid scaling of battery chemical VC/FEC orders beyond initial 2,000 MT capacity.
Risks
- Intense global competition in semiconductor purity levels affecting pricing.
- Raw material cost volatility if China+1 domestic sourcing faces capacity constraints.
Quick takeaway
Extended trial/validation quarter for Jhagadia electrolyte block beyond Q4 FY26.
Risk watch: High debtor days (100) and working capital (111 days) straining liquidity.
Show details (2 drivers, 2 risks)Hide details
Drivers
- Extended trial/validation quarter for Jhagadia electrolyte block beyond Q4 FY26.
- Geopolitical shifts impacting the export-heavy (74%) revenue model.
Risks
- High debtor days (100) and working capital (111 days) straining liquidity.
- Slugish photoresist demand from heraeus affecting Baba Fine Chemicals recovery.
Story of the Stock - Top Strategies
Business Segments
Community
Share your view anonymously. Comments are public and sorted newest first.
Anonymous post · 1500 characters left